Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, granted equity awards effective as of May 8, 2018 , under Fluidigm's
View HTML
Toggle Summary Fluidigm to Participate in Upcoming Investor Events
SOUTH SAN FRANCISCO, Calif. , May 09, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative life science company that develops, manufactures and markets multiparameter mass cytometry technology and proprietary microfluidics systems used in research and applied markets,
View HTML
Toggle Summary Fluidigm Announces First Quarter Financial Results and Operational Progress
Product Innovations in Mass Cytometry and Genomics Total Revenue of $25.2 million , Genomics Revenue Growth of 18 Percent SOUTH SAN FRANCISCO, Calif. , May 03, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced financial results for the first quarter ended March 31, 2018 .
View HTML
Toggle Summary Brad Kreger Joins Fluidigm as Senior Vice President, Global Operations
SOUTH SAN FRANCISCO, Calif. , April 23, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Brad Kreger as Senior Vice President, Global Operations. In this role, Kreger leads global manufacturing, supply chain, demand planning, and distribution for
View HTML
Toggle Summary Fluidigm to Report Q1 2018 Financial Results and Host Conference Call
SOUTH SAN FRANCISCO, Calif. , April 19, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it will report first quarter financial results on Thursday, May 3, 2018 , after the financial markets close. Chris Linthwaite , President and CEO, and Vikram Jog, Chief Financial
View HTML
Toggle Summary Fluidigm Introduces High-Parameter Maxpar Immune Monitoring Panel for Translational and Clinical Research
Providing the industry’s first commercially available high-parameter immune monitoring solution for deep profiling of PBMC, Fluidigm brings proven mass cytometry together with innovative third-party data analysis SOUTH SAN FRANCISCO, Calif. , April 13, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation
View HTML
Toggle Summary Fluidigm Releases CFTR Next-Generation Sequencing Library Prep Assay for Use With the Juno System
SOUTH SAN FRANCISCO, Calif. , April 12, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of the Advanta™ CFTR NGS Library Prep Assay, a highly efficient and scalable next-generation sequencing (NGS) library prep workflow for sequencing of the CFTR (cystic
View HTML
Toggle Summary Fluidigm Announces Exchange of Convertible Notes
SOUTH SAN FRANCISCO, Calif. , March 13, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into separate privately negotiated transactions to exchange approximately $25.0 million in aggregate principal amount of its 2.75% Convertible Senior Notes due
View HTML
Toggle Summary Fluidigm Announces Exchange of Convertible Notes
SOUTH SAN FRANCISCO, Calif. , March 02, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into separate privately negotiated transactions to exchange approximately $125.0 million in aggregate principal amount of its 2.75% Convertible Senior Notes due
View HTML
Toggle Summary Fluidigm to Participate in Upcoming Health Care Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the company's management will participate in two upcoming investor conferences. Chris Linthwaite , President and CEO, and Vikram Jog , Chief Financial Officer, will participate in
View HTML